Search

Your search keyword '"Cabras, Maria Giuseppina"' showing total 46 results
Start Over Author "Cabras, Maria Giuseppina" Publication Year Range Last 10 years
46 results on '"Cabras, Maria Giuseppina"'

1. Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results

Author

Martelli, Maurizio, Ceriani, Luca, Ciccone, Giovannino, Ricardi, Umberto, Kriachok, Iryna, Botto, Barbara, Balzarotti, Monica, Tucci, Alessandra, Usai, Sara Veronica, Zilioli, Vittorio Ruggero, Pennese, Elsa, Arcaini, Luca, Dabrowska-Iwanicka, Anna, Ferreri, Andrés J.M., Merli, Francesco, Zhao, Weili, Rigacci, Luigi, Cellini, Claudia, Hodgson, David, Ionescu, Codruta, Minoia, Carla, Lucchini, Elisa, Spina, Michele, Fosså, Alexander, Janikova, Andrea, Cwynarski, Kate, Mikhaeel, George, Jerkeman, Mats, Di Rocco, Alice, Stepanishyna, Yana, Vitolo, Umberto, Santoro, Armando, Re, Alessandro, Puccini, Benedetta, Olivieri, Jacopo, Petrucci, Luigi, Barrington, Sally F., Malkowski, Bogdan, Metser, Ur, Versari, Annibale, Chauvie, Stephane, Walewski, Jan, Trneny, Marek, Cavalli, Franco, Gospodarowicz, Mary, Johnson, Peter W.M., Davies, Andrew, Zucca, Emanuele, Gospodarowicz, Mary, Hodgson, David, Kuruvilla, John, Wang, Li, Zhao, Weili, Balada, David, Huettmann, Andreas, Angrilli, Francesco, Annibali, Ombretta, Arcaini, Luca, Bagni, Oreste, Balzarotti, Monica, Battistini, Roberta, Botto, Barbara, Cabras, Maria Giuseppina, Calimeri, Teresa, Catello, Califano, Cavallo, Federica, Cellini, Claudia, Ciammella, Patrizia, Consoli, Ugo, De Sanctis, Vitaliana, Di Renzo, Nicola, Di Rocco, Alice, Fabbri, Alberto, Ferrari, Angela, Ferreri, Andrés J.M., Flenghi, Leonardo, Gaidano, Gianluca, Gini, Guido, Gotti, Manuel, Guarini, Attilio, Liberati, Anna Marina, Lucchini, Elisa, Mannina, Donato, Martelli, Maurizio, Matrone, Fabio, Merli, Francesco, Minoia, Carla, Molinari, Anna Lia, Musuraca, Gerardo, Nassi, Luca, Olivieri, Jacopo, Passamonti, Francesco, Pastore, Domenico, Patti, Caterina, Pelliccia, Sabrina, Pennese, Elsa, Petrucci, Luigi, Piazza, Francesco, Pisani, Francesco, Pizzuti, Michele, Pozzi, Samantha, Puccini, Benedetta, Ravano, Emanuele, Re, Alessandro, Re, Francesca, Rigacci, Luigi, Santoro, Armando, Sassone, Marianna, Spina, Michele, Stefoni, Vittorio, Stelitano, Caterina, Tarantini, Giuseppe, Tarella, Corrado, Tucci, Alessandra, Usai, Sara Veronica, Vallisa, Daniele, Vitolo, Umberto, Zaja, Francesco, Zanni, Manuela, Zilioli, Vittorio Ruggero, Fagerli, Un Merete, Fosså, Alexander, Dabrowska-Iwanicka, Anna, Walewski, Jan, DaSilva, Maria Gomes, Jerkeman, Mats, Azinwi, Ngwa Che, Cavalli, Franco, Deantonio, Letizia, Hitz, Felicitas, Ionescu, Codruta, Mingrone, Walter, Moccia, Alden, Novak, Urban, Pirosa, Maria Cristina, Stathis, Anastasios, Zucca, Emanuele, Kriachok, Iryna, Stepanishyna, Yana, Cozens, Kelly, Cwynarski, Kate, Davies, Andrew, Fox, Christopher P., Illidge, Timothy, Johnson, Rod, McKay, Pam, Mikhaeel, George, Milne, Alison, Nimish, Shah, Osborne, Wendy, Paneesha, Shankara, Pettitt, Andrew, Stevens, Don Ambrose, Barrington, Sally F., Stephane Chauvie Bogdan Malkowski, Luca Ceriani, Metser, Ur, Versari, Annibale, Bonomini, Luisella, and Ielmini, Nicoletta

Published
2024
Full Text
View/download PDF

2. IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma

Author

Conconi, Annarita, Chiappella, Annalisa, Ferreri, Andrés J. M., Stathis, Anastasios, Botto, Barbara, Sassone, Marianna, Gaidano, Gianluca, Balzarotti, Monica, Merli, Francesco, Tucci, Alessandra, Vanazzi, Anna, Tani, Monica, Bruna, Riccardo, Orsucci, Lorella, Cabras, Maria Giuseppina, Celli, Melania, Annibali, Ombretta, Liberati, Anna Marina, Zanni, Manuela, Ghiggi, Chiara, Pisani, Francesco, Pinotti, Graziella, Dore, Fausto, Esposito, Fabiana, Pirosa, Maria Cristina, Cesaretti, Marina, Bonomini, Luisella, Vitolo, Umberto, and Zucca, Emanuele

Published
2024
Full Text
View/download PDF

3. MATRix–RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial

Author

Ferreri, Andrés J M, Doorduijn, Jeanette K, Re, Alessandro, Cabras, Maria Giuseppina, Smith, Jeffery, Ilariucci, Fiorella, Luppi, Mario, Calimeri, Teresa, Cattaneo, Chiara, Khwaja, Jahanzaib, Botto, Barbara, Cellini, Claudia, Nassi, Luca, Linton, Kim, McKay, Pam, Olivieri, Jacopo, Patti, Caterina, Re, Francesca, Fanni, Alessandro, Singh, Vikram, Bromberg, Jacoline E C, Cozens, Kelly, Gastaldi, Elisabetta, Bernardi, Massimo, Cascavilla, Nicola, Davies, Andrew, Fox, Christopher P, Frezzato, Maurizio, Osborne, Wendy, Liberati, Anna Marina, Novak, Urban, Zambello, Renato, Zucca, Emanuele, and Cwynarski, Kate

Published
2021
Full Text
View/download PDF

4. IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma

Author

Stathis, Anastasios, primary, Pirosa, Maria Cristina, additional, Orsucci, Lorella, additional, Feugier, Pierre, additional, Tani, Monica, additional, Ghesquières, Hervé, additional, Musuraca, Gerardo, additional, Rossi, Francesca Gaia, additional, Merli, Francesco, additional, Guièze, Romain, additional, Gyan, Emmanuel, additional, Gini, Guido, additional, Marino, Dario, additional, Gressin, Remy, additional, Morschhauser, Franck, additional, Cavallo, Federica, additional, Palombi, Francesca, additional, Conconi, Annarita, additional, Tessoulin, Benoît, additional, Tilly, Hervé, additional, Zanni, Manuela, additional, Cabras, Maria Giuseppina, additional, Capochiani, Enrico, additional, Califano, Catello, additional, Celli, Melania, additional, Pulsoni, Alessandro, additional, Angrilli, Francesco, additional, Occhini, Ubaldo, additional, Casasnovas, René-Olivier, additional, Cartron, Guillaume, additional, Devizzi, Liliana, additional, Haioun, Corinne, additional, Liberati, Anna Marina, additional, Houot, Roch, additional, Merli, Michele, additional, Pietrantuono, Giuseppe, additional, Re, Francesca, additional, Spina, Michele, additional, Landi, Francesco, additional, Cavalli, Franco, additional, Bertoni, Francesco, additional, Rossi, Davide, additional, Ielmini, Nicoletta, additional, Borgo, Elena, additional, Luminari, Stefano, additional, Zucca, Emanuele, additional, and Thieblemont, Catherine, additional

Published
2024
Full Text
View/download PDF

5. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study

Author

Chiappella, Annalisa, Martelli, Maurizio, Angelucci, Emanuele, Brusamolino, Ercole, Evangelista, Andrea, Carella, Angelo Michele, Stelitano, Caterina, Rossi, Giuseppe, Balzarotti, Monica, Merli, Francesco, Gaidano, Gianluca, Pavone, Vincenzo, Rigacci, Luigi, Zaja, Francesco, D'Arco, Alfonso, Cascavilla, Nicola, Russo, Eleonora, Castellino, Alessia, Gotti, Manuel, Congiu, Angela Giovanna, Cabras, Maria Giuseppina, Tucci, Alessandra, Agostinelli, Claudio, Ciccone, Giovannino, Pileri, Stefano A, and Vitolo, Umberto

Published
2017
Full Text
View/download PDF

6. Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma

Author

Ceriani, Luca, Martelli, Maurizio, Zinzani, Pier Luigi, Ferreri, Andrés J.M., Botto, Barbara, Stelitano, Caterina, Gotti, Manuel, Cabras, Maria Giuseppina, Rigacci, Luigi, Gargantini, Livio, Merli, Francesco, Pinotti, Graziella, Mannina, Donato, Luminari, Stefano, Stathis, Anastasios, Russo, Eleonora, Cavalli, Franco, Giovanella, Luca, Johnson, Peter W.M., and Zucca, Emanuele

Published
2015
Full Text
View/download PDF

7. PET-Driven Radiotherapy (RT) in Patients with Low Risk Diffuse Large B-Cell Lymphoma (DLBCL): 5-Year Results of the DLCL10 Multicenter Phase 2 Trial By Fondazione Italiana Linfomi (FIL)

Author

Balzarotti, Monica, primary, Ricardi, Umberto, additional, Spina, Michele, additional, Evangelista, Andrea, additional, Tucci, Alessandra, additional, Cavallo, Federica, additional, Zanni, Manuela, additional, Arcari, Annalisa, additional, Zilioli, Vittorio Ruggero, additional, Sartori, Roberto, additional, Merli, Francesco, additional, Re, Francesca, additional, Vitolo, Umberto, additional, Deidda, Maria Assunta, additional, Melis, Luca, additional, Dessì, Daniela, additional, Rodari, Marcello, additional, Santoro, Armando, additional, Gaidano, Gianluca, additional, Ciccone, Giovannino, additional, Chauvie, Stephane, additional, and Cabras, Maria Giuseppina, additional

Published
2022
Full Text
View/download PDF

8. A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial

Author

Zaccaria, Gian Maria, primary, Ferrero, Simone, additional, Hoster, Eva, additional, Passera, Roberto, additional, Evangelista, Andrea, additional, Genuardi, Elisa, additional, Drandi, Daniela, additional, Ghislieri, Marco, additional, Barbero, Daniela, additional, Del Giudice, Ilaria, additional, Tani, Monica, additional, Moia, Riccardo, additional, Volpetti, Stefano, additional, Cabras, Maria Giuseppina, additional, Di Renzo, Nicola, additional, Merli, Francesco, additional, Vallisa, Daniele, additional, Spina, Michele, additional, Pascarella, Anna, additional, Latte, Giancarlo, additional, Patti, Caterina, additional, Fabbri, Alberto, additional, Guarini, Attilio, additional, Vitolo, Umberto, additional, Hermine, Olivier, additional, Kluin-Nelemans, Hanneke C, additional, Cortelazzo, Sergio, additional, Dreyling, Martin, additional, and Ladetto, Marco, additional

Published
2021
Full Text
View/download PDF

9. Treatment of Patients with Relapsed or Refractory Primary CNS Lymphoma (rrPCNSL) Enrolled in the Randomized Trials of the International Extranodal Lymphoma Study Group (IELSG)

Author

Ferreri, Andrés J M, primary, Cwynarski, Kate, additional, Pulczynski, Elisa, additional, Fox, Christopher P., additional, La Rosée, Paul, additional, Schorb, Elisabeth, additional, Krampera, Mauro, additional, Ilariucci, Fiorella, additional, Orsucci, Lorella, additional, Fabbri, Alberto, additional, Tucci, Alessandra, additional, Roeth, Alexander, additional, Linton, Kim, additional, Binder, Mascha, additional, Hemmaway, Claire, additional, Cabras, Maria Giuseppina, additional, Pinto, Antonio, additional, Calimeri, Teresa, additional, Cavalli, Franco, additional, Zucca, Emanuele, additional, and Illerhaus, Gerald, additional

Published
2021
Full Text
View/download PDF

10. Treatment of Relapsed/Refractory Waldenström Macroglobulinemia Patients: Final Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL)

Author

Benevolo, Giulia, primary, Ferrero, Simone, additional, Villivà, Nicoletta, additional, Castiglione, Anna, additional, Monaco, Federico, additional, Boccomini, Carola, additional, Cabras, Maria Giuseppina, additional, Califano, Catello, additional, Casula, Paolo, additional, Cavallo, Federica, additional, Conconi, Annarita, additional, Drandi, Daniela, additional, Gaidano, Gianluca, additional, Gregorini, Anna Ines, additional, Felici, Stefano, additional, Ferrante, Martina, additional, Mannina, Donato, additional, Molinari, Anna Lia, additional, Musto, Pellegrino, additional, Musuraca, Gerardo, additional, Merli, Michele, additional, Sartori, Roberto, additional, Tani, Monica, additional, Varettoni, Marzia, additional, Vitolo, Umberto, additional, and Orsucci, Lorella, additional

Published
2021
Full Text
View/download PDF

11. Comparison between R-COMP and R-CHOP in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Substudy of the Elderly Project By the Fondazione Italiana Linfomi

Author

Merli, Francesco, primary, Spina, Michele, additional, Tucci, Alessandra, additional, Rigacci, Luigi, additional, Cavallo, Federica, additional, Cabras, Maria Giuseppina, additional, Alvarez, Isabel, additional, Fabbri, Alberto, additional, Re, Alessandro, additional, Puccini, Benedetta, additional, Ferrero, Simone, additional, Usai, Sara Veronica, additional, Ferrari, Angela, additional, Cencini, Emanuele, additional, Pennese, Elsa, additional, Zilioli, Vittorio Ruggero, additional, Marino, Dario, additional, Balzarotti, Monica, additional, Cox, M. Christina, additional, Zanni, Manuela, additional, Di Rocco, Alice, additional, Lleshi, Arben, additional, Botto, Barbara, additional, Hohaus, Stefan, additional, Merli, Michele, additional, Sartori, Roberto, additional, Gini, Guido, additional, Nassi, Luca, additional, Musuraca, Gerardo, additional, Tani, Monica, additional, Bottelli, Chiara, additional, Kovalchuk, Sofia, additional, Re, Francesca, additional, Flenghi, Leonardo, additional, Molinari, Anna Lia, additional, Tarantini, Giuseppe, additional, Chimienti, Emanuela, additional, Marcheselli, Luigi, additional, Mammi, Caterina, additional, Luminari, Stefano, additional, and Arcari, Annalisa, additional

Published
2021
Full Text
View/download PDF

12. CNS Prophylaxis: How Far Is Routine Practice From the Guidelines? Focus on a Nationwide Survey by the Fondazione Italiana Linfomi (FIL)

Author

Gini, Guido, primary, Di Rocco, Alice, additional, Nassi, Luca, additional, Arcari, Annalisa, additional, Tisi, Maria Chiara, additional, Loseto, Giacomo, additional, Olivieri, Attilio, additional, Gentile, Massimo, additional, Annibali, Ombretta, additional, Cabras, Maria Giuseppina, additional, Chiappella, Annalisa, additional, Rusconi, Chiara, additional, Ferreri, Andrés José María, additional, and Balzarotti, Monica, additional

Published
2021
Full Text
View/download PDF

13. Impact of Immunochemotherapy with R-Bendamustine or R-CHOP in the Post-Induction Management of Treatment Naïve Advanced Stage Follicular Lymphoma Patients: A Subset Analysis of the FOLL12 Trial By the Fondazione Italiana Linfomi (FIL)

Author

Luminari, Stefano, primary, Nizzoli, Maria Elena, additional, Chiarenza, Annalisa, additional, Mannina, Donato, additional, Tucci, Alessandra, additional, Boccomini, Carola, additional, Farina, Lucia, additional, Olivieri, Jacopo, additional, Marcheselli, Luigi, additional, Ferrero, Simone, additional, Arcaini, Luca, additional, Pulsoni, Alessandro, additional, Musuraca, Gerardo, additional, Califano, Catello, additional, Merli, Michele, additional, Bari, Alessia, additional, Conconi, Annarita, additional, Re, Francesca, additional, Balzarotti, Monica, additional, Ladetto, Marco, additional, Patti, Caterina, additional, Pinto, Antonello, additional, Cabras, Maria Giuseppina, additional, Musto, Pellegrino, additional, Gini, Guido, additional, Arcari, Annalisa, additional, Manni, Martina, additional, Versari, Annibale, additional, and Federico, Massimo, additional

Published
2021
Full Text
View/download PDF

15. Definition and Validation of the New Elderly Prognostic Index (EPI) for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Geriatric and Clinical Assessment: Results of the Prospective "Elderly Project" on 1353 Patients By the Fondazione Italiana Linfomi

Author

Spina, Michele, primary, Merli, Francesco, primary, Puccini, Benedetta, primary, Cavallo, Federica, primary, Cabras, Maria Giuseppina, primary, Fabbri, Alberto, primary, Angrilli, Francesco, primary, Zilioli, Vittorio Ruggero, primary, Marino, Dario, primary, Balzarotti, Monica, primary, Ladetto, Marco, primary, Cox, M. Christina Christina, primary, Petrucci, Luigi, primary, Arcari, Annalisa, primary, Gini, Guido, primary, Chiappella, Annalisa, primary, Hohaus, Stefan, primary, Musuraca, Gerardo, primary, Merli, Michele, primary, Sartori, Roberto, primary, Nassi, Luca, primary, Tani, Monica, primary, Re, Francesca, primary, Flenghi, Leonardo, primary, Molinari, Anna Lia, primary, Kovalchuk, Sofia, primary, Bottelli, Chiara, primary, Ferrero, Simone, primary, Dessì, Daniela, primary, Cencini, Emanuele, primary, Pennese, Elsa, primary, Tabanelli, Valentina, primary, Marcheselli, Luigi, primary, Mammi, Caterina, primary, Luminari, Stefano, primary, and Tucci, Alessandra, primary

Published
2019
Full Text
View/download PDF

16. The Addition of Bortezomib to R-DHAP Does Not Improve the Response Pre-Stem Cell Transplantation Compared to Standard R-DHAP in Young Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Results of the Phase II Randomized Trial FIL-VERAL12 of the Fondazione Italiana Linfomi

Author

Chiappella, Annalisa, primary, Balzarotti, Monica, additional, Monagheddu, Chiara, additional, Cavallo, Federica, additional, Cabras, Maria Giuseppina, additional, Zanni, Manuela, additional, Califano, Catello, additional, Re, Francesca, additional, Congiu, Angela Giovanna, additional, Corradini, Paolo, additional, Olivieri, Attilio, additional, Liberati, Anna Marina, additional, Volpetti, Stefano, additional, Michieli, Mariagrazia, additional, Tucci, Alessandra, additional, Tani, Monica, additional, Nassi, Luca, additional, Mazza, Rita, additional, Novo, Mattia, additional, Pileri, Stefano A, additional, Ciccone, Giovannino, additional, and Vitolo, Umberto, additional

Published
2019
Full Text
View/download PDF

17. Sequential Matrix-RICE Therapy Followed By Autologous Stem Cell Transplant in Patients with Diffuse Large B-Cell Lymphoma and Secondary Central Nervous System Involvement: The International Extranodal Lymphoma Study Group-42 Phase II (MARIETTA) Trial

Author

Ferreri, Andres JM, primary, Doorduijn, Jeanette K., primary, Cattaneo, Chiara, primary, Cabras, Maria Giuseppina, primary, Smith, Jeffery, primary, Ilariucci, Fiorella, primary, Narni, Franco, primary, Calimeri, Teresa, primary, Re, Alessandro, primary, Khwaja, Jahanzaib, primary, Botto, Barbara, primary, Cellini, Claudia, primary, Nassi, Luca, primary, Linton, Kim, primary, McKay, Pam, primary, Olivieri, Jacopo, primary, Patti, Caterina, primary, Re, Francesca, primary, Fanni, Alessandro, primary, Singh, Vikram, primary, Bromberg, Jacoline, primary, Cozens, Kelly, primary, Gastaldi, Elisabetta, primary, Cascavilla, Nicola, primary, Davies, Andrew, primary, Fox, Christopher P, primary, Frezzato, Maurizio, primary, Osborne, Wendy, primary, Liberati, Anna Marina, primary, Novak, Urban, primary, Zambello, Renato, primary, Zucca, Emanuele, primary, and Cwynarski, Kate, primary

Published
2019
Full Text
View/download PDF

18. O1C.3 Nightshift work and risk of lymphoma subtypes

Author

Cocco, Pierluigi, primary, Satta, Giannina, additional, Meloni, Federico, additional, Betti, Claudia, additional, Zucca, Mariagrazia, additional, Padoan, Marina, additional, Piro, Sara, additional, Gambelunghe, Angela, additional, Miligi, Lucia, additional, Ferri, Giovanni Maria, additional, Magnani, Corrado, additional, Muzi, Giacomo, additional, Cabras, Maria Giuseppina, additional, and Latte, Gian Carlo, additional

Published
2019
Full Text
View/download PDF

20. Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life.

Author

Mulas, Olga, Caocci, Giovanni, Dessì, Daniela, Mantovani, Daniela, Moi, Giulia, Cabras, Maria Giuseppina, and La Nasa, Giorgio

Subjects
MUCOSA-associated lymphoid tissue lymphoma, CASTLEMAN'S disease, DIFFUSE large B-cell lymphomas, RITUXIMAB, OVERALL survival, LYMPHOPROLIFERATIVE disorders, DIAGNOSIS
Abstract

Splenic marginal zone lymphoma (SMZL) is a rare lymphoma belonging to the marginal zone lymphoproliferative disorders. Usually, SMZL occurs with indolent presentation and, when required, the standard of care is represented by rituximab-based regimens. No direct comparison of different rituximab-based combinations and polychemotherapy regimens has been conducted to date. In a monocentric cohort of 68 SMLZ patients, we showed that rituximab in monotherapy or in combination with bendamustine, compared with rituximab associated with the polychemotherapy cycle cyclophosphamide, hydroxydaunorubicin, vincristine and prednisolone (CHOP), resulted in a higher 5-year progression-free survival (91.3 ± 9% and 75 ± 15.7% vs. 30.8 ± 12.1%, p < 0.001). Platelets at diagnosis <100 ×109/L (p = 0.034, HR = 4.3) and transformation into diffuse large B-cell lymphoma (p = 0.031, HR = 4.3) were associated with a lower overall survival. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

21. AISF position paper on HCV in immunocompromised patients

Author

Marzano, Alfredo, primary, Angelucci, Emanuele, additional, Astegiano, Marco, additional, Baratelli, Chiara, additional, Biancone, Luigi, additional, Bironzo, Paolo, additional, Brancaccio, Giuseppina, additional, Brunetto, Maurizia Rossana, additional, Bruno, Raffaele, additional, Burra, Patrizia, additional, Cabras, Maria Giuseppina, additional, Caraceni, Paolo, additional, Chialà, Claudia, additional, Clemente, Maria Grazia, additional, Colli, Agostino, additional, Daniele, Bruno, additional, De Gasperi, Elisabetta, additional, Di Marco, Vito, additional, Ditto, Maria Chiara, additional, Fagiuoli, Stefano, additional, Ferri, Clodoveo, additional, Gaeta, Giovanni Battista, additional, Grossi, Paolo Antonio, additional, Imperatrice, Barbara, additional, Lampertico, Pietro, additional, Macaluso, Fabio Salvatore, additional, Madonia, Salvatore, additional, Marignani, Massimo, additional, Mazzarelli, Chiara, additional, Mella, Alberto, additional, Missale, Gabriele, additional, Parisi, Simone, additional, Pasulo, Luisa, additional, Puoti, Massimo, additional, Rendina, Maria, additional, Ribaldone, Davide, additional, Rossi, Giuseppe, additional, Toniutto, Pierluigi, additional, Tucci, Alessandra, additional, Vajro, Pietro, additional, Viganò, Mauro, additional, Volpes, Riccardo, additional, and Zignego, Anna Linda, additional

Published
2019
Full Text
View/download PDF

22. Romidepsin-CHOEP Plus Intensification with up-Front Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: Final Results of Phase Ib PTCL13 Study of the Fondazione Italiana Linfomi

Author

Chiappella, Annalisa, primary, Carniti, Cristiana, additional, Evangelista, Andrea, additional, Cabras, Maria Giuseppina, additional, Re, Alessandro, additional, Zanni, Manuela, additional, Stefoni, Vittorio, additional, Santoro, Armando, additional, Congiu, Angela Giovanna, additional, Dodero, Anna, additional, Pileri, Stefano A., additional, Ciccone, Giovannino, additional, and Corradini, Paolo, additional

Published
2018
Full Text
View/download PDF

23. The Engineered MIPI (e-MIPI), a Candidate Data-Mining Based Mantle Cell Lymphoma Prognostic Index Developed from the Dataset of the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial

Author

Zaccaria, Gian Maria, primary, Ferrero, Simone, additional, Passera, Roberto, additional, Evangelista, Andrea, additional, Loschirico, Mariella, additional, Dogliotti, Irene, additional, Ghislieri, Marco, additional, Genuardi, Elisa, additional, Bomben, Riccardo, additional, Gattei, Valter, additional, Ciccone, Giovannino, additional, Tani, Monica, additional, Gaidano, Gianluca, additional, Volpetti, Stefano, additional, Cabras, Maria Giuseppina, additional, Di Renzo, Nicola, additional, Merli, Francesco, additional, Vallisa, Daniele, additional, Spina, Michele, additional, Pascarella, Anna, additional, Latte, Giancarlo, additional, Patti, Caterina, additional, Pozzato, Gabriele, additional, Fabbri, Alberto, additional, Cortelazzo, Sergio, additional, and Ladetto, Marco, additional

Published
2018
Full Text
View/download PDF

24. Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL) for Relapsed/Refractory Waldenström Macroglobulinemia Patients

Author

Benevolo, Giulia, primary, Ferrero, Simone, additional, Andriani, Alessandro, additional, Castiglione, Anna, additional, Baraldi, Anna, additional, Boccomini, Carola, additional, Cabras, Maria Giuseppina, additional, Califano, Catello, additional, Cavallo, Federica, additional, Conconi, Annarita, additional, Curreli, Luigi, additional, Drandi, Daniela, additional, Gaidano, Gianluca, additional, Felici, Stefano, additional, Ferrante, Martina, additional, Mannina, Donato, additional, Merli, Michele, additional, Molinari, Anna Lia, additional, Musto, Pellegrino, additional, Musuraca, Gerardo, additional, Rossi, Francesca Gaia, additional, Sartori, Roberto, additional, Tani, Monica, additional, Varettoni, Marzia, additional, Vitolo, Umberto, additional, and Orsucci, Lorella, additional

Published
2018
Full Text
View/download PDF

25. Early Progression As a Predictor of Survival in Marginal Zone Lymphomas: An Analysis from the Prospective International NF10 Study By Fondazione Italiana Linfomi

Author

Luminari, Stefano, primary, Marcheselli, Luigi, additional, Defrancesco, Irene, additional, Rattotti, Sara, additional, Cesaretti, Marina, additional, Frigeni, Marco, additional, Sciarra, Roberta, additional, Cavallo, Federica, additional, Deodato, Marina, additional, Cabras, Maria Giuseppina, additional, Merli, Michele, additional, Ferrari, Angela, additional, Re, Francesca, additional, Spina, Michele, additional, Cencini, Emanuele, additional, Annibali, Ombretta, additional, Pulsoni, Alessandro, additional, Delamain, Marcia Torresan, additional, Mannina, Donato, additional, Gaidano, Gianluca, additional, Stelitano, Caterina, additional, Ferrari, Daris, additional, Visco, Carlo, additional, Angrilli, Francesco, additional, Tarantino, Vittoria, additional, and Arcaini, Luca, additional

Published
2018
Full Text
View/download PDF

26. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study

Author

Iannitto, Emilio, primary, Bellei, Monica, additional, Amorim, Sandy, additional, Ferreri, Andrés J. M., additional, Marcheselli, Luigi, additional, Cesaretti, Marina, additional, Haioun, Corinne, additional, Mancuso, Salvatrice, additional, Bouabdallah, Krimo, additional, Gressin, Remy, additional, Tripodo, Claudio, additional, Traverse‐Glehen, Alexandra, additional, Baseggio, Lucile, additional, Zupo, Simonetta, additional, Stelitano, Caterina, additional, Castagnari, Barbara, additional, Patti, Caterina, additional, Alvarez, Isabel, additional, Liberati, Anna Marina, additional, Merli, Michele, additional, Gini, Guido, additional, Cabras, Maria Giuseppina, additional, Dupuis, Jean, additional, Tessoulin, Benoit, additional, Perrot, Aurore, additional, Re, Francesca, additional, Palombi, Francesca, additional, Gulino, Alessandro, additional, Zucca, Emanuele, additional, Federico, Massimo, additional, and Thieblemont, Catherine, additional

Published
2018
Full Text
View/download PDF

27. Gene Polymorphisms, Activation of the Aryl Hydrocarbon Receptor, and DNA Damage: A Preliminary Investigation

Author

Amini Nia, Shadi, primary, Satta, Giannina, additional, Intranuovo, Grazianna, additional, Sanna, Sonia, additional, Zucca, Mariagrazia, additional, Culurgioni, Fabio, additional, Cabras, Maria Giuseppina, additional, Sogos, Valeria, additional, Ferri, Giovanni Maria, additional, Ennas, Maria Grazia, additional, and Cocco, Pierluigi, additional

Published
2018
Full Text
View/download PDF

28. Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers

Author

Lucioni, Marco, primary, Berti, Emilio, additional, Arcaini, Luca, additional, Croci, Giorgio A., additional, Maffi, Aldo, additional, Klersy, Catherine, additional, Goteri, Gaia, additional, Tomasini, Carlo, additional, Quaglino, Pietro, additional, Riboni, Roberta, additional, Arra, Mariarosa, additional, Dallera, Elena, additional, Grandi, Vieri, additional, Alaibac, Mauro, additional, Ramponi, Antonio, additional, Rattotti, Sara, additional, Cabras, Maria Giuseppina, additional, Franceschetti, Silvia, additional, Fraternali-Orcioni, Giulio, additional, Zerbinati, Nicola, additional, Onida, Francesco, additional, Ascani, Stefano, additional, Fierro, Maria Teresa, additional, Rupoli, Serena, additional, Gambacorta, Marcello, additional, Zinzani, Pier Luigi, additional, Pimpinelli, Nicola, additional, Santucci, Marco, additional, and Paulli, Marco, additional

Published
2016
Full Text
View/download PDF

29. Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study

Author

Arcari, Annalisa, primary, Chiappella, Annalisa, additional, Spina, Michele, additional, Zanlari, Luca, additional, Bernuzzi, Patrizia, additional, Valenti, Vanessa, additional, Tani, Monica, additional, Marasca, Roberto, additional, Cabras, Maria Giuseppina, additional, Zambello, Renato, additional, Santagostino, Alberto, additional, Ilariucci, Fiorella, additional, Carli, Giuseppe, additional, Musto, Pellegrino, additional, Savini, Paolo, additional, Marino, Dario, additional, Ghio, Francesco, additional, Gentile, Massimo, additional, Cox, Maria Christina, additional, and Vallisa, Daniele, additional

Published
2015
Full Text
View/download PDF

30. Khorana Score and Histotype Predict the Incidence of Early Venous Thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). a Pooled Data Analysis of Twelve Clinical Trials of Fondazione Italiana Linfomi (FIL)

Author

Santi, Roberto Mario, primary, Ceccarelli, Manuela, additional, Catania, Gioacchino, additional, Monagheddu, Chiara, additional, Evangelista, Andrea, additional, Bernocco, Elisa, additional, Monaco, Federico, additional, Federico, Massimo, additional, Vitolo, Umberto, additional, Cortelazzo, Sergio, additional, Cabras, Maria Giuseppina, additional, Spina, Michele, additional, Baldini, Luca, additional, Boccomini, Carola, additional, Chiappella, Annalisa, additional, Bari, Alessia, additional, Luminari, Stefano, additional, Calabrese, Marco, additional, Levis, Alessandro, additional, Contino, Laura, additional, Ciccone, Giovannino, additional, and Ladetto, Marco, additional

Published
2015
Full Text
View/download PDF

31. High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial

Author

Ferreri, Andrés J.M., primary, Donadoni, Giovanni, additional, Cabras, Maria Giuseppina, additional, Patti, Caterina, additional, Mian, Michael, additional, Zambello, Renato, additional, Tarella, Corrado, additional, Di Nicola, Massimo, additional, D'Arco, Alfonso M., additional, Doa, Gianluca, additional, Bruno-Ventre, Marta, additional, Assanelli, Andrea, additional, Foppoli, Marco, additional, Citterio, Giovanni, additional, Fanni, Alessandro, additional, Mulè, Antonino, additional, Caligaris-Cappio, Federico, additional, and Ciceri, Fabio, additional

Published
2015
Full Text
View/download PDF

33. Bendamustine in Combination with Rituximab As First-Line Treatment of Splenic Marginal Zone Lymphoma (BRISMA). Results of the IELSG-36 Phase II Study

Author

Iannitto, Emilio, Bellei, Monica, Ferreri, Andrés J M, Marcheselli, Luigi, Cesaretti, Marina, Haioun, Corinne, Mancuso, Salvatrice, Bouabdallah, Krimo, Gressin, Remy, Tripodo, Claudio, traverse-Glehen, Alexandra, Baseggio, Lucile, Zupo, Simonetta, Stelitano, Caterina, Castagnari, Barbara, Patti, Caterina, Merli, Francesco, Liberati, Anna Marina, Merli, Michele, Gini, Guido, Cabras, Maria Giuseppina, Dupuis, Jehan, Re, Francesca, Zucca, Emanuele, Federico, Massimo, and Thieblemont, Catherine

Published
2017
Full Text
View/download PDF

34. ABC Subtype, TP53 Mutation and BCL2 Overexpression are Associated with a Worse Outcome in Untreated Poor-Risk Young Diffuse Large B-Cell Lymphoma: Results from the Frontline Phase III BIO-DLBCL04 Study of the Fondazione Italiana Linfomi

Author

Chiappella, Annalisa, Agostinelli, Claudio, Ladetto, Marco, Evangelista, Andrea, Martelli, Maurizio, Angelucci, Emanuele, Balzarotti, Monica, Bomben, Riccardo, Cabras, Maria Giuseppina, Diop, Fary, Fabbri, Marco, Gotti, Manuel, Melle, Federica, Merli, Francesco, Motta, Giovanna, Nassi, Luca, Novero, Domenico, Righi, Simona, Rossi, Davide, Rossi, Giuseppe, Stelitano, Caterina, Gattei, Valter, Gaidano, Gianluca, Pileri, Stefano A., and Vitolo, Umberto

Published
2017
Full Text
View/download PDF

35. IELSG-38: A Phase II Study of Chlorambucil in Combination with Rituximab Followed By Maintenance Therapy with Subcutaneous Rituximab in Patients with Extranodal Marginal Zone B-Cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT)

Author

Stathis, Anastasios, Gregorini, Anna, Gressin, Remy, Orsucci, Lorella, Perrot, Aurore, Tani, Monica, Coiffier, Bertrand, Musuraca, Gerardo, Guieze, Romain, Marino, Dario, Gini, Guido, Ferrari, Angela, Gyan, Emmanuel, Morschhauser, Franck, Palombi, Francesca, Cavallo, Federica, Le Gouill, Steven, Tilly, Herve, Salvi, Flavia, Conconi, Annarita, Cabras, Maria Giuseppina, Capochiani, Enrico, Califano, Catello, Molinari, Anna Lia, Pulsoni, Alessandro, Ielmini, Nicoletta, Luminari, Stefano, Cavalli, Franco, Zucca, Emanuele, and Thieblemont, Catherine

Published
2017
Full Text
View/download PDF

36. Outcome of Patients with Gamma Delta T Cell Lymphomas: Analysis of 1429 Cases Registered in the Prospective T-Cell Project

Author

Foss, Francine M, Horwitz, Steven M., Bellei, Monica, Manni, Martina, Tarantino, Vittoria, Shustov, Andrei R., Dlouhy, Ivan, Cabrera, Maria Elena, Kim, Won Seog, Hitz, Felicitas, Gabus, Raul, Gutierrez, Antonio, Varela, Sabela Bobillo, Vitolo, Umberto, Merli, Francesco, Ballova, Veronika, Davies, Andrew, Cabras, Maria Giuseppina, Di Raimondo, Francesco, and Federico, Massimo

Published
2017
Full Text
View/download PDF

37. Real Life Data on Clinical Aspects and Treatment of Marginal Zone Lymphoma: An Analysis from the NF10 Project, an International, Prospective, Observational Study of the Fondazione Italiana Linfomi

Author

Defrancesco, Irene, Marcheselli, Luigi, Rattotti, Sara, Cesaretti, Marina, Frigeni, Marco, Sciarra, Roberta, Cavallo, Federica, Tedeschi, Alessandra, Cabras, Maria Giuseppina, Merli, Michele, Ferrari, Angela, Re, Francesca, Spina, Michele, Cencini, Emanuele, Annibali, Ombretta, Cimino, Giuseppe, Delamain, Marcia Torresan, Mannina, Donato, Gaidano, Gianluca, Stelitano, Caterina, Ferrari, Daris, Visco, Carlo, Angrilli, Francesco, Tarantino, Vittoria, Luminari, Stefano, and Arcaini, Luca

Published
2017
Full Text
View/download PDF

38. Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study.

Author

Arcari, Annalisa, Chiappella, Annalisa, Spina, Michele, Zanlari, Luca, Bernuzzi, Patrizia, Valenti, Vanessa, Tani, Monica, Marasca, Roberto, Cabras, Maria Giuseppina, Zambello, Renato, Santagostino, Alberto, Ilariucci, Fiorella, Carli, Giuseppe, Musto, Pellegrino, Savini, Paolo, Marino, Dario, Ghio, Francesco, Gentile, Massimo, Cox, Maria Christina, and Vallisa, Daniele

Subjects
LYMPHOMA treatment, RITUXIMAB, MONOCLONAL antibodies, INFLIXIMAB, STEM cell transplantation
Abstract

Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not suitable for high dose chemotherapy with autologous stem cell transplantation (ASCT) has a dismal prognosis and no standard therapy. We designed an Italian multicenter retrospective study aimed at evaluating the safety and efficacy of rituximab plus bendamustine (R–B) as salvage treatment in patients not eligible for ASCT because of age and/or comorbidity or in patients with post-ASCT recurrence. Fifty-five patients with a median age of 76 years were included. The overall response rate was 50%, including 28% complete remission and 22% partial remission. The median overall survival (OS) was 10.8 months. The median progression free survival (PFS) was 8.8 months. Eleven patients are still alive and in complete remission at last follow-up (12–71 months). Toxicity was moderate, mainly grades 1 and 2. R–B showed promising efficacy results with an acceptable toxicity profile and should be further investigated, possibly in combination with novel drugs. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

39. Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL).

Author

Tucci, Alessandra, Martelli, Maurizio, Rigacci, Luigi, Riccomagno, Paola, Cabras, Maria Giuseppina, Salvi, Flavia, Stelitano, Caterina, Fabbri, Alberto, Storti, Sergio, Fogazzi, Stefano, Mancuso, Salvatrice, Brugiatelli, Maura, Fama, Angelo, Paesano, Paolo, Puccini, Benedetta, Bottelli, Chiara, Dalceggio, Daniela, Bertagna, Francesco, Rossi, Giuseppe, and Spina, Michele

Subjects
GERIATRIC assessment, LYMPHOMAS, ANTIGEN presenting cells, OLDER patients
Abstract

We performed a multicenter study to validate the concept that a simple comprehensive geriatric assessment (CGA) can identify elderly, non-fit patients with diffuse large B-cell lymphoma (DLBCL) in whom curative treatment is not better then palliation, and to analyze potential benefits of treatment modulation after further subdividing the non-fit category by CGA criteria. One hundred and seventy-three patients aged > 69 treated with curative or palliative intent by clinical judgement only were grouped according to CGA into fit (46%), unfit (16%) and frail (38%) categories. Two-year overall survival (OS) was significantly better in fit than in non-fit patients (84% vs. 47%; p < 0.0001). Survival in unfit and frail patients was not significantly different. Curative treatment slightly improved 2-year OS in unfit (75% vs. 45%) but not in frail patients (44% vs. 39%). CGA was confirmed as very efficient in identifying elderly patients with DLBCL who can benefit from a curative approach. Further efforts are needed to better tailor therapies in non-fit patients. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

40. Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas

Author

Santi, Roberto Mario, Ceccarelli, Manuela, Bernocco, Elisa, Monagheddu, Chiara, Evangelista, Andrea, Valeri, Federica, Monaco, Federico, Vitolo, Umberto, Cortelazzo, Sergio, Cabras, Maria Giuseppina, Spina, Michele, Baldini, Luca, Boccomini, Carola, Chiappella, Annalisa, Bari, Alessia, Luminari, Stefano, Visco, Carlo, Calabrese, Marco, Limberti, Giulia, Levis, Alessandro, Contino, Laura, Ciccone, Giovannino, and Ladetto, Marco

Published
2017
Full Text
View/download PDF

41. A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial.

Author

Zaccaria, Gian Maria, Ferrero, Simone, Hoster, Eva, Passera, Roberto, Evangelista, Andrea, Genuardi, Elisa, Drandi, Daniela, Ghislieri, Marco, Barbero, Daniela, Del Giudice, Ilaria, Tani, Monica, Moia, Riccardo, Volpetti, Stefano, Cabras, Maria Giuseppina, Di Renzo, Nicola, Merli, Francesco, Vallisa, Daniele, Spina, Michele, Pascarella, Anna, and Latte, Giancarlo

Subjects
MACHINE learning, RANDOMIZED controlled trials, SURVIVAL analysis (Biometry), LYMPHOMAS, CLUSTER analysis (Statistics), ALGORITHMS
Abstract

Simple Summary: The interest in using Machine-Learning (ML) techniques in clinical research is growing. We applied ML to build up a novel prognostic model from patients affected with Mantle Cell Lymphoma (MCL) enrolled in a phase III open-labeled, randomized clinical trial from the Fondazione Italiana Linfomi (FIL)—MCL0208. This is the first application of ML in a prospective clinical trial on MCL lymphoma. We applied a novel ML pipeline to a large cohort of patients for which several clinical variables have been collected at baseline, and assessed their prognostic value based on overall survival. We validated it on two independent data series provided by European MCL Network. Due to its flexibility, we believe that ML would be of tremendous help in the development of a novel MCL prognostic score aimed at re-defining risk stratification. Background: Multicenter clinical trials are producing growing amounts of clinical data. Machine Learning (ML) might facilitate the discovery of novel tools for prognostication and disease-stratification. Taking advantage of a systematic collection of multiple variables, we developed a model derived from data collected on 300 patients with mantle cell lymphoma (MCL) from the Fondazione Italiana Linfomi-MCL0208 phase III trial (NCT02354313). Methods: We developed a score with a clustering algorithm applied to clinical variables. The candidate score was correlated to overall survival (OS) and validated in two independent data series from the European MCL Network (NCT00209222, NCT00209209); Results: Three groups of patients were significantly discriminated: Low, Intermediate (Int), and High risk (High). Seven discriminants were identified by a feature reduction approach: albumin, Ki-67, lactate dehydrogenase, lymphocytes, platelets, bone marrow infiltration, and B-symptoms. Accordingly, patients in the Int and High groups had shorter OS rates than those in the Low and Int groups, respectively (Int→Low, HR: 3.1, 95% CI: 1.0–9.6; High→Int, HR: 2.3, 95% CI: 1.5–4.7). Based on the 7 markers, we defined the engineered MCL international prognostic index (eMIPI), which was validated and confirmed in two independent cohorts; Conclusions: We developed and validated a ML-based prognostic model for MCL. Even when currently limited to baseline predictors, our approach has high scalability potential. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

42. The Metabolomic Profile of Lymphoma Subtypes: A Pilot Study.

Author

Barberini, Luigi, Noto, Antonio, Fattuoni, Claudia, Satta, Giannina, Zucca, Mariagrazia, Cabras, Maria Giuseppina, Mura, Ester, and Cocco, Pierluigi

Subjects
GAS chromatography/Mass spectrometry (GC-MS), CHRONIC lymphocytic leukemia, LYMPHOMAS, HODGKIN'S disease, MULTIPLE myeloma, PILOT projects, CD30 antigen
Abstract

Lymphoma defines a group of different diseases. This study examined pre-treatment plasma samples from 66 adult patients (aged 20–74) newly diagnosed with any lymphoma subtype, and 96 frequency matched population controls. We used gas chromatography-mass spectrometry (GC-MS) to compare the metabolic profile by case/control status and across the major lymphoma subtypes. We conducted univariate and multivariate analyses, and partial least square discriminant analysis (PLS-DA). When compared to the controls, statistically validated models were obtained for diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and Hodgkin lymphoma (HL), but not follicular lymphoma (FL). The metabolomic analysis highlighted interesting differences between lymphoma patients and population controls, allowing the discrimination between pathologic and healthy subjects: Important metabolites, such as hypoxanthine and elaidic acid, were more abundant in all lymphoma subtypes. The small sample size of the individual lymphoma subtypes prevented obtaining PLS-DA validated models, although specific peculiar features of each subtype were observed; for instance, fatty acids were most represented in MM and HL patients, while 2-aminoadipic acid, 2-aminoheptanedioic acid, erythritol, and threitol characterized DLBCL and CLL. Metabolomic analysis was able to highlight interesting differences between lymphoma patients and population controls, allowing the discrimination between pathologic and healthy subjects. Further studies are warranted to understand whether the peculiar metabolic patterns observed might serve as early biomarkers of lymphoma. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

43. AISF position paper on HCV in immunocompromised patients

Author

Gabriele Missale, Mauro Viganò, Marco Astegiano, Mauro Salizzoni, C. Chialà, Angelo Pera, Patrizia Racca, Massimo Di Maio, Mario Salomone, M. Puoti, Simone Parisi, Paolo Bironzo, M. Rendina, Carla Pasquina, Clodoveo Ferri, Luisa Pasulo, Rita Tozzi, A. Tucci, Pietro Lampertico, Emanuele Angelucci, Bruno Daniele, Patrizia Burra, Franco Riccardini, Marco Lagget, Fabio Salvatore Macaluso, Davide Giuseppe Ribaldone, Luca Miele, Clara Lisa Peroni, Raffaele Bruno, Anna Linda Zignego, Ambrogio Orlando, Giovanni Battista Gaeta, Giuseppe Montrucchio, Daniela Libertucci, Massimo Marignani, Agostino Colli, Enrico Fusaro, Antonio Craxì, Giorgio Maria Saracco, Barbara Imperatrice, Paolo Caraceni, Luisa Giaccone, Chiara Baratelli, Giuliano Torre, Luigi Biancone, Elisabetta De Gasperi, Mario Rizzetto, Maria Grazia Clemente, Francesco Paolo Russo, Aldo Giacardi, Riccardo Volpes, Edoardo G. Giannini, Daniele Curci, Rossella Della Valle, Salvatore Petta, Pierluigi Toniutto, Alessandro Busca, Pietro Vajro, Giorgio Verme, Chiara Mazzarelli, Paolo Grossi, Maria Chiara Ditto, Lorella Orsucci, Umberto Vitolo, Alberto Mella, Salvatore Madonia, Federica Cavallo, Maria Giuseppina Cabras, Stefano Bonora, Massimiliano Conforti, Vito Di Marco, Mario Pirisi, Giuseppe Cariti, Marta Coscia, Giuseppina Brancaccio, L. Scaglione, Stefano Fagiuoli, Alfredo Marzano, Stefano Cusinato, Roberto Minutolo, Giuseppe Rossi, Enrico Brignardello, Maurizia Rossana Brunetto, Marzano A., Angelucci E., Astegiano M., Baratelli C., Biancone L., Bironzo P., Brancaccio G., Brunetto M.R., Bruno R., Burra P., Cabras M.G., Caraceni P., Chiala C., Clemente M.G., Colli A., Daniele B., De Gasperi E., Di Marco V., Ditto M.C., Fagiuoli S., Ferri C., Gaeta G.B., Grossi P.A., Imperatrice B., Lampertico P., Macaluso F.S., Madonia S., Marignani M., Mazzarelli C., Mella A., Missale G., Parisi S., Pasulo L., Puoti M., Rendina M., Ribaldone D., Rossi G., Toniutto P., Tucci A., Vajro P., Vigano M., Volpes R., Zignego A.L., Giannini E.G., Miele L., Russo F.P., Petta S., Bonora S., Brignardello E., Busca A., Cariti G., Cavallo F., Conforti M., Coscia M., Craxi A., Curci D., Cusinato S., Di Maio M., Valle R.D., Fusaro E., Giacardi A., Giaccone L., Lagget M., Libertucci D., Minutolo R., Montrucchio G., Orlando A., Orsucci L., Pasquina C., Pera A., Peroni C.L., Pirisi M., Racca P., Riccardini F., Rizzetto M., Salizzoni M., Salomone M., Saracco G.M., Scaglione L., Torre G., Tozzi R., Vitolo U., Verme G., Angelucci, E, Astegiano, M, Baratelli, C, Biancone, L, Bironzo, P, Brancaccio, G, Brunetto, M, Bruno, R, Burra, P, Cabras, M, l Caraceni, P, Chialà, C, Clemente, M, Colli, A, Daniele, B, De Gasperi, E, Di Marco, V, Ditto, M, Fagiuoli, S, Ferri, C, Gaeta, G, Grossi, P, Imperatrice, B, Lampertico, P, Macaluso, F, Madonia, S, Marignani, M, Mazzarelli, C, Mella, A, Missale, G, Parisi, S, Pasulo, L, Puoti, M, Rendina, M, Ribaldone, D, Rossi, G, Toniutto, P, Tucci, A, Vajro, P, Viganò, M, Volpes, R, Zignego, A, Giannini, E, Miele, L, Russo, F, Petta, S, Bonora, S, Brignardello, E, Busca, A, Cariti, G, Cavallo, F, Conforti, M, Coscia, M, Craxì, A, Curci, D, Cusinato, S, Di Maio, M, Valle, R, Fusaro, E, Giacardi, A, Giaccone, L, Lagget, M, Libertucci, D, Minutolo, R, Montrucchio, G, Orlando, A, Orsucci, L, Pasquina, C, Pera, A, Peroni, C, Pirisi, M, Racca, P, Riccardini, F, Rizzetto, M, Salizzoni, M, Salomone, M, Saracco, G, Scaglione, L, Torre, G, Tozzi, R, Vitolo, U, Verme, G, Marzano, Alfredo, Angelucci, Emanuele, Astegiano, Marco, Baratelli, Chiara, Biancone, Luigi, Bironzo, Paolo, Brancaccio, Giuseppina, Brunetto, Maurizia Rossana, Bruno, Raffaele, Burra, Patrizia, Cabras, Maria Giuseppina, Caraceni, Paolo, Chialà, Claudia, Clemente, Maria Grazia, Colli, Agostino, Daniele, Bruno, De Gasperi, Elisabetta, Di Marco, Vito, Ditto, Maria Chiara, Fagiuoli, Stefano, Ferri, Clodoveo, Gaeta, Giovanni Battista, Grossi, Paolo Antonio, Imperatrice, Barbara, Lampertico, Pietro, Macaluso, Fabio Salvatore, Madonia, Salvatore, Marignani, Massimo, Mazzarelli, Chiara, Mella, Alberto, Missale, Gabriele, Parisi, Simone, Pasulo, Luisa, Puoti, Massimo, Rendina, Maria, Ribaldone, Davide, Rossi, Giuseppe, Toniutto, Pierluigi, Tucci, Alessandra, Vajro, Pietro, Viganò, Mauro, Volpes, Riccardo, Zignego, Anna Linda, Giannini, Edoardo G., Miele, Luca, Russo, Francesco Paolo, Petta, Salvatore, Bonora, Stefano, Brignardello, Enrico, Busca, Alessandro, Cariti, Giuseppe, Cavallo, Federica, Conforti, Massimiliano, Coscia, Marta, Craxì, Antonio, Curci, Daniele, Cusinato, Stefano, Di Maio, Massimo, Valle, Rossella Della, Fusaro, Enrico, Giacardi, Aldo, Giaccone, Luisa, Lagget, Marco, Libertucci, Daniela, Minutolo, Roberto, Montrucchio, Giuseppe, Orlando, Ambrogio, Orsucci, Lorella, Pasquina, Carla, Pera, Angelo, Peroni, Clara Lisa, Pirisi, Mario, Racca, Patrizia, Riccardini, Franco, Rizzetto, Mario, Salizzoni, Mauro, Salomone, Mario, Saracco, Giorgio Maria, Scaglione, Luca, Torre, Giuliano, Tozzi, Rita, Vitolo, Umberto, Verme, Giorgio, and Ditto, MARIA CHIARA

Subjects
medicine.medical_specialty, Transplant Recipient, Comorbidity, Antiviral Agents, Organ transplantation, 03 medical and health sciences, Immunocompromised Host, 0302 clinical medicine, Internal medicine, Neoplasms, medicine, Immunocompromised patient, Humans, Chronic, Intensive care medicine, Antiviral Agent, Hepatology, business.industry, Gastroenterology, Hepatitis C, Chronic, medicine.disease, Hepatitis C, Organ transplant, HCV, Immunocompromised patients, Transplant Recipients, Immunocompetence, Italy, 030220 oncology & carcinogenesis, HCV, Immunocompromised patients, Organ transplant, Position paper, Neoplasm, 030211 gastroenterology & hepatology, business, Direct acting, Human
Abstract

This report summarizes the clinical features and the indications for treating HCV infection in immunocompromised and transplanted patients in the Direct Acting Antiviral drugs era.

Published
2018

44. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): Final results of a multicentre, open-label, randomised, controlled, phase 3 study

Author

Claudio Agostinelli, Nicola Cascavilla, Monica Balzarotti, Ercole Brusamolino, Gianluca Gaidano, Alessia Castellino, Annalisa Chiappella, Giovannino Ciccone, Luigi Rigacci, Francesco Zaja, Caterina Stelitano, Andrea Evangelista, Alessandra Tucci, Angela Congiu, Eleonora Russo, Manuel Gotti, Stefano Pileri, Giuseppe Rossi, Maria Giuseppina Cabras, Maurizio Martelli, Angelo Michele Carella, Emanuele Angelucci, Vincenzo Pavone, Umberto Vitolo, Alfonso Maria D'Arco, Francesco Merli, Chiappella, Annalisa, Martelli, Maurizio, Angelucci, Emanuele, Brusamolino, Ercole, Evangelista, Andrea, Carella, Angelo Michele, Stelitano, Caterina, Rossi, Giuseppe, Balzarotti, Monica, Merli, Francesco, Gaidano, Gianluca, Pavone, Vincenzo, Rigacci, Luigi, Zaja, Francesco, D'Arco, Alfonso, Cascavilla, Nicola, Russo, Eleonora, Castellino, Alessia, Gotti, Manuel, Congiu, Angela Giovanna, Cabras, Maria Giuseppina, Tucci, Alessandra, Agostinelli, Claudio, Ciccone, Giovannino, Pileri, Stefano A, and Vitolo, Umberto

Subjects
Male, Dose-dense chemotherapy, Intention to Treat Analysi, Gastroenterology, Dexamethasone, Antibodies, Monoclonal, Murine-Derived, 0302 clinical medicine, Autologous stem-cell transplantation, International Prognostic Index, Risk Factors, Antineoplastic Combined Chemotherapy Protocols, Melphalan, Etoposide, education.field_of_study, Cytarabine, Induction Chemotherapy, Middle Aged, Intention to Treat Analysis, Transplantation, Autologou, Survival Rate, Oncology, Vincristine, 030220 oncology & carcinogenesis, Female, Lymphoma, Large B-Cell, Diffuse, Rituximab, Human, medicine.drug, Adult, medicine.medical_specialty, DLBCL, Treatment, Population, Transplantation, Autologous, Disease-Free Survival, Follow-Up Studie, 03 medical and health sciences, Internal medicine, medicine, Humans, education, Cyclophosphamide, Survival rate, Carmustine, Antineoplastic Combined Chemotherapy Protocol, business.industry, Risk Factor, Induction chemotherapy, Hematologic Disease, Hematologic Diseases, Surgery, Consolidation Chemotherapy, Transplantation, Doxorubicin, Prednisone, Mitoxantrone, business, Follow-Up Studies, Stem Cell Transplantation, 030215 immunology
Abstract

Summary Background The prognosis of young patients with diffuse large B-cell lymphoma at high risk (age-adjusted International Prognostic Index [aa-IPI] score 2 or 3) treated with R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) is poor. The aim of this study was to investigate the possible benefit of intensification with high-dose chemotherapy and autologous stem-cell transplantation as part of first-line treatment in these patients. Methods We did a multicentre, open-label, randomised, controlled, phase 3 trial with a 2 × 2 factorial design to compare, at two different R-CHOP dose levels, a full course of rituximab-dose-dense chemotherapy (no transplantation group) versus an abbreviated course of rituximab-dose-dense chemotherapy followed by consolidation with R-MAD (rituximab plus high-dose cytarabine plus mitoxantrone plus dexamethasone) and high-dose BEAM chemotherapy (carmustine, etoposide, cytarabine, and melphalan) plus autologous stem-cell transplantation (transplantation group) in young patients (18–65 years) with untreated high-risk diffuse large B-cell lymphoma (aa-IPI score 2–3). At enrolment, patients were stratified according to aa-IPI score and randomly assigned (1:1:1:1) to receive R-CHOP (intravenous rituximab 375 mg/m 2 , cyclophosphamide 750 mg/m 2 , doxorubicin 50 mg/m 2 , and vincristine 1·4 mg/m 2 on day 1, plus oral prednisone 100 mg on days 1–5) delivered in a 14-day cycle (R-CHOP-14) for eight cycles; high-dose R-CHOP-14 (R-MegaCHOP-14; R-CHOP-14 except for cyclophosphamide 1200 mg/m 2 and doxorubicin 70 mg/m 2 ) for six cycles; R-CHOP-14 for four cycles followed by R-MAD (intravenous rituximab 375 mg/m 2 on day 1 or 4 plus intravenous cytarabine 2000 mg/m 2 and dexamethasone 4 mg/m 2 every 12 h on days 1–3 plus intravenous mitoxantrone 8 mg/m 2 on days 1–3) plus BEAM (intravenous carmustine 300 mg/m 2 on day −7, intravenous cytarabine 200 mg/m 2 twice a day on days −6 to −3, intravenous etoposide 100 mg/m 2 twice a day on days −6 to −3, plus intravenous melphalan 140 mg/m 2 on day −2) and autologous stem-cell transplantation (day 0); or R-MegaCHOP-14 for four cycles followed by R-MAD plus BEAM and autologous stem-cell transplantation. The primary endpoint was failure-free survival at 2 years in the intention-to-treat population. This study is registered with EudraCT (2005-002181-14; 2007-000275-42) and with ClinicalTrials.gov, number NCT00499018. Findings Between Jan 10, 2006, and Sept 8, 2010, 399 patients were randomly assigned to receive transplantation (n=199) or no transplantation (n=200); 203 patients were assigned to receive R-CHOP-14 and 196 were assigned to receive R-MegaCHOP-14. With a median follow-up of 72 months (IQR 57–88), 2-year failure-free survival was 71% (95% CI 64–77) in the transplantation group versus 62% (95% CI 55–68) in the no transplantation group (hazard ratio [HR] 0·65 [95% CI 0·47–0·91]; stratified log-rank test p=0·012). No difference in 5-year overall survival was observed between these groups (78% [95% CI 71–83] versus 77% [71–83]; HR 0·98 [0·65–1·48]; stratified log-rank test p=0·91). Grade 3 or worse haematological adverse events were reported in 183 (92%) of 199 patients in the transplantation group versus 135 (68%) of 200 patients in the no transplantation group. Grade 3 or worse non-haematological adverse events were reported in 90 (45%) versus 31 (16%); the most common grade 3 or worse non-haematological adverse event was gastrointestinal (49 [25%] vs 19 [10%]). Treatment-related deaths occurred in 13 (3%) patients; eight in the transplantation group and five in the no transplantation group. Interpretation Abbreviated rituximab-dose-dense chemotherapy plus R-MAD plus BEAM and autologous stem-cell transplantation reduced the risk of treatment failure compared with full course rituximab-dose-dense chemotherapy in young patients with diffuse large B-cell lymphoma at high risk. However, these results might not be clinically meaningful, since this improvement did not reflect an improvement in overall survival. These results do not support further consideration of the use of intensification of R-CHOP as an upfront strategy in patients with diffuse large B-cell lymphoma with poor prognosis. Funding Fondazione Italiana Linfomi.

Published
2017

45. Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers

Author

Emilio Berti, Aldo Maffi, Pier Luigi Zinzani, Elena Dallera, G. Fraternali-Orcioni, Sara Rattotti, Marco Lucioni, Silvia Franceschetti, Maria Giuseppina Cabras, Francesco Onida, Roberta Riboni, Serena Rupoli, Marco Paulli, Pietro Quaglino, Mariarosa Arra, Marco Santucci, Marcello Gambacorta, Maria Teresa Fierro, Nicola Zerbinati, Giorgio Alberto Croci, Nicola Pimpinelli, Antonio Ramponi, Mauro Alaibac, Luca Arcaini, Carlo Tomasini, Catherine Klersy, Stefano Ascani, Vieri Grandi, Gaia Goteri, Lucioni, Marco, Berti, Emilio, Arcaini, Luca, Croci, Giorgio A., Maffi, Aldo, Klersy, Catherine, Goteri, Gaia, Tomasini, Carlo, Quaglino, Pietro, Riboni, Roberta, Arra, Mariarosa, Dallera, Elena, Grandi, Vieri, Alaibac, Mauro, Ramponi, Antonio, Rattotti, Sara, Cabras, Maria Giuseppina, Franceschetti, Silvia, Fraternali Orcioni, Giulio, Zerbinati, Nicola, Onida, Francesco, Ascani, Stefano, Fierro, Maria Teresa, Rupoli, Serena, Gambacorta, Marcello, Zinzani, PIER LUIGI, Pimpinelli, Nicola, Santucci, Marco, and Paulli, Marco

Subjects
Male, Pathology, Cancer Research, Skin Neoplasms, BCL2, Cutaneous lymphoma, Follicular lymphoma, Large cell lymphoma, Leg type, Oncology, Radiology, Nuclear Medicine and Imaging, cutaneous lymphoma, follicular lymphoma, large cell lymphoma, leg type, Adult, Aged, Aged, 80 and over, Biomarkers, Tumor, Diagnosis, Differential, Female, Humans, Interferon Regulatory Factors, Lymphoma, B-Cell, Middle Aged, Neprilysin, Prognosis, Proto-Oncogene Proteins c-bcl-6, Proto-Oncogene Proteins c-myc, Retrospective Studies, Survival Analysis, 030207 dermatology & venereal diseases, 0302 clinical medicine, Nuclear Medicine and Imaging, hemic and lymphatic diseases, Centroblasts, Original Research, Not Otherwise Specified, Large-cell lymphoma, BCL6, Marginal zone, 030220 oncology & carcinogenesis, Radiology, medicine.medical_specialty, 03 medical and health sciences, medicine, Radiology, Nuclear Medicine and imaging, business.industry, Clinical Cancer Research, medicine.disease, Lymphoma, business
Abstract

Categorization of primary cutaneous B‐cell lymphomas (PCBCL) other than marginal zone (MZL) represents a diagnostic challenge with relevant prognostic implications. The 2008 WHO lymphoma classification recognizes only primary cutaneous follicular center cell lymphoma (PCFCCL) and primary cutaneous diffuse large B‐cell lymphoma, leg type (PCDLBCL‐LT), whereas the previous 2005 WHO/EORTC classification also included an intermediate form, namely PCDLBCL, other. We conducted a retrospective, multicentric, consensus‐based revision of the clinicopathologic characteristics of 161 cases of PCBCL other than MZL. Upon the histologic features that are listed in the WHO classification, 96 cases were classified as PCFCCL and 25 as PCDLBCL‐LT; 40 further cases did not fit in the former subgroups in terms of cytology and/or architecture, thus were classified as PCDLBCL, not otherwise specified (PCDLBCL‐NOS). We assigned all the cases a histogenetic profile, based on the immunohistochemical detection of CD10, BCL6, and MUM1, and a “double hit score” upon positivity for BCL2 and MYC. PCDLBCL‐NOS had a clinical presentation more similar to PCFCCL, whereas the histology was more consistent with the picture of a diffuse large B‐cell lymphoma, as predominantly composed of centroblasts but with intermixed a reactive infiltrate of small lymphocytes. Its behavior was intermediate between the other two forms, particularly when considering only cases with a “non‐germinal B‐cell” profile, whereas “germinal center” cases resembled PCFCCL. Our data confirmed the aggressive behavior of PCDLBC‐LT, which often coexpressed MYC and BCL2. The impact of single factors on 5‐year survival was documented, particularly histogenetic profile in PCDLBCL and BCL2 translocation in PCFCCL. Our study confirms that a further group—PCDLBCL‐NOS—exists, which can be recognized through a careful combination of histopathologic criteria coupled with adequate clinical information.

Published
2016

46. Activation of the aryl hydrocarbon receptor and risk of lymphoma subtypes.

Author

Sanna S, Satta G, Padoan M, Piro S, Gambelunghe A, Miligi L, Ferri GM, Magnani C, Muzi G, Rigacci L, Cabras MG, Angelucci E, Latte GC, Gabbas A, Ennas MG, and Cocco P

Abstract

The aryl hydrocarbon receptor (AhR) is a transcription factor implicated in several pathways known to be relevant in lymphomagenesis. Aim of our study was to explore the link between AhR activation and risk of lymphoma subtypes. We used a Dual-Luciferase Assay ® and a luminometer to detect the activation of the luciferase gene, in HepG2 cells transfected with a specific reporter systems, by a 50 ml serum aliquot of cases of diffuse large B cell lymphoma (N = 108), follicular lymphoma (N = 85), chronic lymphocytic leukemia (N = 72), multiple myeloma (N = 80), and Hodgkin lymphoma (N = 94) and 357 controls who participated in the multicentre Italian study on gene-environment interactions in lymphoma etiology (ItGxE). Risk of each lymphoma subtype associated with AhR activation was calculated with polytomous logistic regression adjusting by age, gender, and study centre. The overall prevalence of AhR activation ranged 13.9-23.6% by subtype, and it varied by study area (8-39%). Risk associated with AhR activation was moderately elevated for follicular lymphoma (OR = 1.56, 95% CI 0.86, 2.80) and chronic lymphocytic leukemia (OR = 1.56, 95% CI 0.83, 2.96). Despite our inconclusive findings about the association with risk of lymphoma subtypes, we showed that the Dual-Luciferase Assay can be reliably and easily applied in population-based studies to detect AhR activation., Competing Interests: None.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results